OctoPlus announces agreement with a US biotechnology company on its controlled release technology
Advertisement
OctoPlus N.V. announced that it has signed an agreement with a US biotechnology company relating to the use of OctoPlus' controlled release technology.
Under the contract, OctoPlus will develop a controlled release version of a product currently in clinical development using its proprietary drug delivery technology PolyActive®. The client will reimburse OctoPlus for its activities under the agreement. Further financial terms of the agreement are not disclosed.